Navigation Links
AMRI Signs Agreement for Exclusive License of its Tubulin Inhibitor Program for Cancer
Date:2/11/2013

fety, tolerability, and pharmacokinetic profile and document effects on tumor growth. Previously announced results from the Phase I clinical dose-escalation study indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

About Bessor Pharma and Chai Therapeutics

Bessor Pharma LLC and its affiliate, Chai Therapeutics, LLC, founded by a team of R&D and pharmaceutical business leaders, has created and is utilizing a new model for drug development and value creation, with a focus on translating drug discovery/development opportunities from universities and other organizations to key value points, typically IND readiness and for select projects, clinical proof-of-concept. The company has developed a flexible, project-oriented, capital efficient appr
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deborah Morosini, MD Pathologist and Patient Advocate Signs on as Medical Director and Advisory Board Member of Store-A-Tooth™ Dental Stem Cell Banking
2. Trade Show Display Co. GLM Displays Redesigns Blog
3. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
4. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
5. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
6. Ben-Gurion University develops side-illuminated ultra-efficient solar cell designs
7. Bluechiip Signs Strategic Partnership with Gentris Corporation
8. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
9. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
10. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... even the entire body to visualize long-range connections between ... a long-time dream of biologists. A study published by ... Cell has now made that dream a ... and human tissue biopsies transparent, while keeping the cellular ... way for a better understanding of brain-body interactions, more ...
(Date:7/31/2014)... July 31, 2014 Rogne Bioscience, a privately-held ... Area , has acquired a licence to anti-inflammatory ... company. The potent anti-inflammatory activity of the peptides was ... University of Oxford,s Sir William Dunn School ... raised over $1.5 million in seed financing, is developing ...
(Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... today the integration of Omicsoft’s Array Suite with ... platforms will be able to send data in tranSMART ... works with all versions of tranSMART including the new ... art statistics, visualization and storage for the analysis of ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... Thursday, November 5, 2009 at 4:30 p.m. Eastern Time ... OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... third quarter and nine months ended September 30, 2009 ... of 2009. , The following consolidated results reflect the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... financial results for the third quarter ended September 30, ... September of this year, the FDA,s Arthritis Advisory Committee ... of XIAFLEX(TM) for the treatment of Dupuytren,s disease, and ...
... Texas, Nov. 5 Wound Management Technologies, Inc., (WNDM), announced ... to purchase all healthcare-related assets of Virtual Health Technologies, Inc. ... be paid $1,000,000 in cash and debt, 4,000,000 shares of ... on the Veriscrip technology being acquired from VHGI. ...
Cached Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
(Date:7/31/2014)... genes to the earliest common ancestor of butterflies ... an extensive "Tree of Lepidoptera" in the first ... , Among the study,s more surprising findings: Butterflies ... to large ones, which completely changes scientists, understanding ... that some insects once classified as moths are ...
(Date:7/31/2014)... It has long been known that biomass burning ... savannah as a ritual , slash-and-burn agriculture and ... public health. , But until the release of ... Environmental Engineering Professor Mark Z. Jacobson, the degree ... , Jacobson,s research, detailed in a paper published ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... A tale of two sisters has helped researchers solve ... causes an inherited form of the lung disease Pulmonary Alveolar ... Journal of Experimental Medicine , a research team led ... possibility of an inhaled therapy to overcome a chain of ...
... at the Johns Hopkins Bloomberg School of Public ... for potential human exposure to antibiotic-resistant bacteria from ... chickens from farm to slaughterhouse. A study by ... bacteria, both susceptible and drug-resistant, on surfaces and ...
... exercise seems to reduce anger expression in overweight but ... study on the topic looked at 208 typically sedentary ... afterschool aerobic exercise program or maintained their usual inactive ... common anger expressions such as slamming doors and hitting, ...
Cached Biology News:Inherited genetic cause, possible treatment found for complex lung disorder 2Inherited genetic cause, possible treatment found for complex lung disorder 3Transporting broiler chickens could spread antibiotic-resistant organisms 2Exercise helps overweight children reduce anger expression 2
...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... Experion software, PC, is used ... the data obtained from the Experion ... data in electropherogram and simulated gel ... other calculations in a Results table. ...
Biology Products: